Next Generation Cancer Diagnostics - Global Market Outlook (2015-2022)

Next Generation Cancer Diagnostics - Global Market Outlook (2015-2022)

  • Published: March 2016
  • ID: SMRC15626

According to Stratistics MRC, the Global Next Generation Cancer Diagnostics market is estimated at $2.95 billion in 2015 and is expected to grow at a CAGR of 32.6% to reach $20.93 billion by 2022. Growing incidence of oncology diseases is expected to boost the demand for next generation cancer diagnostic tests market. However, lack of sufficient reimbursement policies for novel technologies and stringent regulatory procedures are the major factors that can hamper the global next generation cancer diagnostics market growth over the forecast period.

The largest segment of the global market for next generation cancer diagnostics is Blood-born cancers. Asia Pacific is likely to be one of the fastest growing regions of this sector and is anticipated to grow at a lucrative rate. A largely untouched market base which has exhibited technological advancements in healthcare research during the past decade is responsible for rapid growth in this region.

Some of the key players in the global Next Generation Cancer Diagnostics market are Thermo Fisher Scientific, Inc., Roche, Philips Electronics NV, Perkin Elmer Inc., Novartis AG, Lab-on-a-chip, Illumina, Inc., Agilent Technologies Inc, Siemens Healthcare, Johnson & Johnson, Hologic Inc., GE Healthcare, C.R. Bard, Inc and Abbot.

Cancer Type Covered:
• Lung Cancer
• Colorectal Cancer
• Cervical Cancer
• Breast Cancer
• Other Cancer Types

Functions Covered:
• Therapeutic Monitoring 
• Risk analysis 
• Prognostics diagnosis 
• Companion Diagnostics 
• Cancer Screening 

Technologies Covered:
• Platform-Based Diagnostics  
o Polymerase Chain Reaction (PCR)
o Next-Generation Sequencing (NGS)
o Microarrays
o In Situ Hybridization (ISH)
o Immunohistochemistry (IHC)
o Flow Cytometry
o Other Technologies
•  Instrument-Based
o Diagnostic Imaging
o Ultrasound
o Mammography
•  Biopsies

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK 
o Spain     
o Rest of Europe 
• Asia Pacific
o Japan       
o China       
o India       
o Australia       
o New Zealand      
o Rest of Asia Pacific      
• Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

1 Executive Summary
  
2 Preface 

 2.1 Abstract
 2.2 Stake Holders
 2.3 Research Scope
 2.4 Research Methodology
  2.4.1 Data Mining
  2.4.2 Data Analysis
  2.4.3 Data Validation
  2.4.4 Research Approach
 2.5 Research Sources
  2.5.1 Primary Research Sources
  2.5.2 Secondary Research Sources
  2.5.3 Assumptions
  
3 Market Trend Analysis
 3.1 Introduction
 3.2 Drivers
 3.3 Restraints
 3.4 Opportunities
 3.5 Threats
 3.6 Application Analysis
 3.7 Technology Analysis
 3.8 Emerging markets
  
4 Porters Five Force Analysis
 4.1 Bargaining power of suppliers
 4.2 Bargaining power of buyers
 4.3 Threat of substitutes
 4.4 Threat of new entrants
 4.5 Competitive rivalry
  
5 Global Next Generation Cancer Diagnostics Market, By Application
 5.1 Introduction
 5.2 Proteomic Analysis
 5.3 Epigenetic Analysis
 5.4 Genetic Analysis
 5.5 Biomarker Development
 5.6 CTC Analysis
  
6 Global Next Generation Cancer Diagnostics Market, By Technology
 6.1 Introduction
 6.2 Lab-on-a-chip
 6.3 DNA Microarrays
 6.4 Multiplexed assays
 6.5 RT-PCR & Multiplexing
 6.6 Protein Microarrays
 6.7 Cellular capture and identification
 6.8 Next Generation Sequencing
 6.9 Benchtop Sequencers
 6.10 Other Technologies
  
7 Global Next Generation Cancer Diagnostics Market, By Function
 7.1 Introduction
 7.2 Prognosis Diagnostics
 7.3 Companion Diagnostics
 7.4 Cancer Screening
 7.5 Risk Analysis
 7.6 Therapeutic Monitoring
  
8 Global Next Generation Cancer Diagnostics Market, By Cancer Type
 8.1 Introduction
 8.2 Sex-related tumors
  8.2.1 Cervical Cancer
  8.2.2 Breast Cancer
  8.2.3 Ovarian Cancer
  8.2.4 Prostate Cancer
 8.3 Blood-born cancers
  8.3.1 Myeloma
  8.3.2 Leukemia
  8.3.3 Lymphoma
 8.4 Lung Cancer
 8.5 Solid tumors
 8.6 Colorectal Cancer
 8.7 Other Cancers
  
9 Global Next Generation Cancer Diagnostics Market, By Geography
 9.1 North America
  9.1.1 US
  9.1.2 Canada
  9.1.3 Mexico
 9.2 Europe
  9.2.1 Germany
  9.2.2 France
  9.2.3 Italy
  9.2.4 UK
  9.2.5 Spain
  9.2.6 Rest of Europe
 9.3 Asia Pacific
  9.3.1 Japan
  9.3.2 China
  9.3.3 India
  9.3.4 Australia
  9.3.5 New Zealand
  9.3.6 Rest of Asia Pacific
 9.4 Rest of the World
  9.4.1 Middle East
  9.4.2 Brazil
  9.4.3 Argentina
  9.4.4 South Africa
  9.4.5 Egypt
  
10 Key Developments
 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
 10.2 Acquisitions & Mergers
 10.3 New Product Launch
 10.4 Expansions
 10.5 Other Key Strategies
  
11 Company Profiling
 11.1 Abbott Laboratories
 11.2 Agilent Technologies Inc
 11.3 GE Healthcare
 11.4 Genomic Health Inc.
 11.5 Hologic Inc.
 11.6 Illumina Inc.
 11.7 Johnson & Johnson
 11.8 Myriad Genetics Inc.
 11.9 Novartis AG
 11.10 Opko Health Inc.
 11.11 Perkin Elmer Inc.
 11.12 Philips Electronics NV
 11.13 Qiagen
 11.14 Roche Holding AG
 11.15 Thermo Fisher Scientific Inc.


List of Tables 
1 Global Next Generation Cancer Diagnostics Market Outlook, By Region (2013-2022) ($MN)
2 Global Next Generation Cancer Diagnostics Market Outlook, By Application (2013-2022) ($MN)
3 Global Next Generation Cancer Diagnostics Market Outlook, By Proteomic Analysis (2013-2022) ($MN)
4 Global Next Generation Cancer Diagnostics Market Outlook, By Epigenetic Analysis (2013-2022) ($MN)
5 Global Next Generation Cancer Diagnostics Market Outlook, By Genetic Analysis (2013-2022) ($MN)
6 Global Next Generation Cancer Diagnostics Market Outlook, By Biomarker Development (2013-2022) ($MN)
7 Global Next Generation Cancer Diagnostics Market Outlook, By CTC Analysis (2013-2022) ($MN)
8 Global Next Generation Cancer Diagnostics Market Outlook, By Technology (2013-2022) ($MN)
9 Global Next Generation Cancer Diagnostics Market Outlook, By Lab-on-a-chip (2013-2022) ($MN)
10 Global Next Generation Cancer Diagnostics Market Outlook, By DNA Microarrays (2013-2022) ($MN)
11 Global Next Generation Cancer Diagnostics Market Outlook, By Multiplexed assays (2013-2022) ($MN)
12 Global Next Generation Cancer Diagnostics Market Outlook, By RT-PCR & Multiplexing (2013-2022) ($MN)
13 Global Next Generation Cancer Diagnostics Market Outlook, By Protein Microarrays (2013-2022) ($MN)
14 Global Next Generation Cancer Diagnostics Market Outlook, By Cellular capture and identification (2013-2022) ($MN)
15 Global Next Generation Cancer Diagnostics Market Outlook, By Next Generation Sequencing (2013-2022) ($MN)
16 Global Next Generation Cancer Diagnostics Market Outlook, By Benchtop Sequencers (2013-2022) ($MN)
17 Global Next Generation Cancer Diagnostics Market Outlook, By Other Technologies (2013-2022) ($MN)
18 Global Next Generation Cancer Diagnostics Market Outlook, By Function (2013-2022) ($MN)
19 Global Next Generation Cancer Diagnostics Market Outlook, By Prognosis Diagnostics (2013-2022) ($MN)
20 Global Next Generation Cancer Diagnostics Market Outlook, By Companion Diagnostics (2013-2022) ($MN)
21 Global Next Generation Cancer Diagnostics Market Outlook, By Cancer Screening (2013-2022) ($MN)
22 Global Next Generation Cancer Diagnostics Market Outlook, By Risk Analysis (2013-2022) ($MN)
23 Global Next Generation Cancer Diagnostics Market Outlook, By Therapeutic Monitoring (2013-2022) ($MN)
24 Global Next Generation Cancer Diagnostics Market Outlook, By Cancer Type (2013-2022) ($MN)
25 Global Next Generation Cancer Diagnostics Market Outlook, By Sex-related tumors (2013-2022) ($MN)
26 Global Next Generation Cancer Diagnostics Market Outlook, By Cervical Cancer (2013-2022) ($MN)
27 Global Next Generation Cancer Diagnostics Market Outlook, By Breast Cancer (2013-2022) ($MN)
28 Global Next Generation Cancer Diagnostics Market Outlook, By Ovarian Cancer (2013-2022) ($MN)
29 Global Next Generation Cancer Diagnostics Market Outlook, By Prostate Cancer (2013-2022) ($MN)
30 Global Next Generation Cancer Diagnostics Market Outlook, By Blood-born cancers (2013-2022) ($MN)
31 Global Next Generation Cancer Diagnostics Market Outlook, By Myeloma (2013-2022) ($MN)
32 Global Next Generation Cancer Diagnostics Market Outlook, By Leukemia (2013-2022) ($MN)
33 Global Next Generation Cancer Diagnostics Market Outlook, By Lymphoma (2013-2022) ($MN)
34 Global Next Generation Cancer Diagnostics Market Outlook, By Lung Cancer (2013-2022) ($MN)
35 Global Next Generation Cancer Diagnostics Market Outlook, By Solid tumors (2013-2022) ($MN)
36 Global Next Generation Cancer Diagnostics Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
37 Global Next Generation Cancer Diagnostics Market Outlook, By Other Cancers (2013-2022) ($MN)
38 North America Next Generation Cancer Diagnostics Market Outlook, By Application (2013-2022) ($MN)
39 North America Next Generation Cancer Diagnostics Market Outlook, By Proteomic Analysis (2013-2022) ($MN)
40 North America Next Generation Cancer Diagnostics Market Outlook, By Epigenetic Analysis (2013-2022) ($MN)
41 North America Next Generation Cancer Diagnostics Market Outlook, By Genetic Analysis (2013-2022) ($MN)
42 North America Next Generation Cancer Diagnostics Market Outlook, By Biomarker Development (2013-2022) ($MN)
43 North America Next Generation Cancer Diagnostics Market Outlook, By CTC Analysis (2013-2022) ($MN)
44 North America Next Generation Cancer Diagnostics Market Outlook, By Technology (2013-2022) ($MN)
45 North America Next Generation Cancer Diagnostics Market Outlook, By Lab-on-a-chip (2013-2022) ($MN)
46 North America Next Generation Cancer Diagnostics Market Outlook, By DNA Microarrays (2013-2022) ($MN)
47 North America Next Generation Cancer Diagnostics Market Outlook, By Multiplexed assays (2013-2022) ($MN)
48 North America Next Generation Cancer Diagnostics Market Outlook, By RT-PCR & Multiplexing (2013-2022) ($MN)
49 North America Next Generation Cancer Diagnostics Market Outlook, By Protein Microarrays (2013-2022) ($MN)
50 North America Next Generation Cancer Diagnostics Market Outlook, By Cellular capture and identification (2013-2022) ($MN)
51 North America Next Generation Cancer Diagnostics Market Outlook, By Next Generation Sequencing (2013-2022) ($MN)
52 North America Next Generation Cancer Diagnostics Market Outlook, By Benchtop Sequencers (2013-2022) ($MN)
53 North America Next Generation Cancer Diagnostics Market Outlook, By Other Technologies (2013-2022) ($MN)
54 North America Next Generation Cancer Diagnostics Market Outlook, By Function (2013-2022) ($MN)
55 North America Next Generation Cancer Diagnostics Market Outlook, By Prognosis Diagnostics (2013-2022) ($MN)
56 North America Next Generation Cancer Diagnostics Market Outlook, By Companion Diagnostics (2013-2022) ($MN)
57 North America Next Generation Cancer Diagnostics Market Outlook, By Cancer Screening (2013-2022) ($MN)
58 North America Next Generation Cancer Diagnostics Market Outlook, By Risk Analysis (2013-2022) ($MN)
59 North America Next Generation Cancer Diagnostics Market Outlook, By Therapeutic Monitoring (2013-2022) ($MN)
60 North America Next Generation Cancer Diagnostics Market Outlook, By Cancer Type (2013-2022) ($MN)
61 North America Next Generation Cancer Diagnostics Market Outlook, By Sex-related tumors (2013-2022) ($MN)
62 North America Next Generation Cancer Diagnostics Market Outlook, By Cervical Cancer (2013-2022) ($MN)
63 North America Next Generation Cancer Diagnostics Market Outlook, By Breast Cancer (2013-2022) ($MN)
64 North America Next Generation Cancer Diagnostics Market Outlook, By Ovarian Cancer (2013-2022) ($MN)
65 North America Next Generation Cancer Diagnostics Market Outlook, By Prostate Cancer (2013-2022) ($MN)
66 North America Next Generation Cancer Diagnostics Market Outlook, By Blood-born cancers (2013-2022) ($MN)
67 North America Next Generation Cancer Diagnostics Market Outlook, By Myeloma (2013-2022) ($MN)
68 North America Next Generation Cancer Diagnostics Market Outlook, By Leukemia (2013-2022) ($MN)
69 North America Next Generation Cancer Diagnostics Market Outlook, By Lymphoma (2013-2022) ($MN)
70 North America Next Generation Cancer Diagnostics Market Outlook, By Lung Cancer (2013-2022) ($MN)
71 North America Next Generation Cancer Diagnostics Market Outlook, By Solid tumors (2013-2022) ($MN)
72 North America Next Generation Cancer Diagnostics Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
73 North America Next Generation Cancer Diagnostics Market Outlook, By Other Cancers (2013-2022) ($MN)
74 Europe Next Generation Cancer Diagnostics Market Outlook, By Application (2013-2022) ($MN)
75 Europe Next Generation Cancer Diagnostics Market Outlook, By Proteomic Analysis (2013-2022) ($MN)
76 Europe Next Generation Cancer Diagnostics Market Outlook, By Epigenetic Analysis (2013-2022) ($MN)
77 Europe Next Generation Cancer Diagnostics Market Outlook, By Genetic Analysis (2013-2022) ($MN)
78 Europe Next Generation Cancer Diagnostics Market Outlook, By Biomarker Development (2013-2022) ($MN)
79 Europe Next Generation Cancer Diagnostics Market Outlook, By CTC Analysis (2013-2022) ($MN)
80 Europe Next Generation Cancer Diagnostics Market Outlook, By Technology (2013-2022) ($MN)
81 Europe Next Generation Cancer Diagnostics Market Outlook, By Lab-on-a-chip (2013-2022) ($MN)
82 Europe Next Generation Cancer Diagnostics Market Outlook, By DNA Microarrays (2013-2022) ($MN)
83 Europe Next Generation Cancer Diagnostics Market Outlook, By Multiplexed assays (2013-2022) ($MN)
84 Europe Next Generation Cancer Diagnostics Market Outlook, By RT-PCR & Multiplexing (2013-2022) ($MN)
85 Europe Next Generation Cancer Diagnostics Market Outlook, By Protein Microarrays (2013-2022) ($MN)
86 Europe Next Generation Cancer Diagnostics Market Outlook, By Cellular capture and identification (2013-2022) ($MN)
87 Europe Next Generation Cancer Diagnostics Market Outlook, By Next Generation Sequencing (2013-2022) ($MN)
88 Europe Next Generation Cancer Diagnostics Market Outlook, By Benchtop Sequencers (2013-2022) ($MN)
89 Europe Next Generation Cancer Diagnostics Market Outlook, By Other Technologies (2013-2022) ($MN)
90 Europe Next Generation Cancer Diagnostics Market Outlook, By Function (2013-2022) ($MN)
91 Europe Next Generation Cancer Diagnostics Market Outlook, By Prognosis Diagnostics (2013-2022) ($MN)
92 Europe Next Generation Cancer Diagnostics Market Outlook, By Companion Diagnostics (2013-2022) ($MN)
93 Europe Next Generation Cancer Diagnostics Market Outlook, By Cancer Screening (2013-2022) ($MN)
94 Europe Next Generation Cancer Diagnostics Market Outlook, By Risk Analysis (2013-2022) ($MN)
95 Europe Next Generation Cancer Diagnostics Market Outlook, By Therapeutic Monitoring (2013-2022) ($MN)
96 Europe Next Generation Cancer Diagnostics Market Outlook, By Cancer Type (2013-2022) ($MN)
97 Europe Next Generation Cancer Diagnostics Market Outlook, By Sex-related tumors (2013-2022) ($MN)
98 Europe Next Generation Cancer Diagnostics Market Outlook, By Cervical Cancer (2013-2022) ($MN)
99 Europe Next Generation Cancer Diagnostics Market Outlook, By Breast Cancer (2013-2022) ($MN)
100 Europe Next Generation Cancer Diagnostics Market Outlook, By Ovarian Cancer (2013-2022) ($MN)
101 Europe Next Generation Cancer Diagnostics Market Outlook, By Prostate Cancer (2013-2022) ($MN)
102 Europe Next Generation Cancer Diagnostics Market Outlook, By Blood-born cancers (2013-2022) ($MN)
103 Europe Next Generation Cancer Diagnostics Market Outlook, By Myeloma (2013-2022) ($MN)
104 Europe Next Generation Cancer Diagnostics Market Outlook, By Leukemia (2013-2022) ($MN)
105 Europe Next Generation Cancer Diagnostics Market Outlook, By Lymphoma (2013-2022) ($MN)
106 Europe Next Generation Cancer Diagnostics Market Outlook, By Lung Cancer (2013-2022) ($MN)
107 Europe Next Generation Cancer Diagnostics Market Outlook, By Solid tumors (2013-2022) ($MN)
108 Europe Next Generation Cancer Diagnostics Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
109 Europe Next Generation Cancer Diagnostics Market Outlook, By Other Cancers (2013-2022) ($MN)
110 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Application (2013-2022) ($MN)
111 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Proteomic Analysis (2013-2022) ($MN)
112 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Epigenetic Analysis (2013-2022) ($MN)
113 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Genetic Analysis (2013-2022) ($MN)
114 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Biomarker Development (2013-2022) ($MN)
115 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By CTC Analysis (2013-2022) ($MN)
116 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Technology (2013-2022) ($MN)
117 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Lab-on-a-chip (2013-2022) ($MN)
118 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By DNA Microarrays (2013-2022) ($MN)
119 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Multiplexed assays (2013-2022) ($MN)
120 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By RT-PCR & Multiplexing (2013-2022) ($MN)
121 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Protein Microarrays (2013-2022) ($MN)
122 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Cellular capture and identification (2013-2022) ($MN)
123 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Next Generation Sequencing (2013-2022) ($MN)
124 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Benchtop Sequencers (2013-2022) ($MN)
125 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Other Technologies (2013-2022) ($MN)
126 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Function (2013-2022) ($MN)
127 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Prognosis Diagnostics (2013-2022) ($MN)
128 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Companion Diagnostics (2013-2022) ($MN)
129 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Cancer Screening (2013-2022) ($MN)
130 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Risk Analysis (2013-2022) ($MN)
131 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Therapeutic Monitoring (2013-2022) ($MN)
132 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Cancer Type (2013-2022) ($MN)
133 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Sex-related tumors (2013-2022) ($MN)
134 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Cervical Cancer (2013-2022) ($MN)
135 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Breast Cancer (2013-2022) ($MN)
136 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Ovarian Cancer (2013-2022) ($MN)
137 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Prostate Cancer (2013-2022) ($MN)
138 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Blood-born cancers (2013-2022) ($MN)
139 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Myeloma (2013-2022) ($MN)
140 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Leukemia (2013-2022) ($MN)
141 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Lymphoma (2013-2022) ($MN)
142 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Lung Cancer (2013-2022) ($MN)
143 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Solid tumors (2013-2022) ($MN)
144 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
145 Asia Pacific Next Generation Cancer Diagnostics Market Outlook, By Other Cancers (2013-2022) ($MN)
146 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Application (2013-2022) ($MN)
147 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Proteomic Analysis (2013-2022) ($MN)
148 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Epigenetic Analysis (2013-2022) ($MN)
149 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Genetic Analysis (2013-2022) ($MN)
150 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Biomarker Development (2013-2022) ($MN)
151 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By CTC Analysis (2013-2022) ($MN)
152 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Technology (2013-2022) ($MN)
153 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Lab-on-a-chip (2013-2022) ($MN)
154 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By DNA Microarrays (2013-2022) ($MN)
155 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Multiplexed assays (2013-2022) ($MN)
156 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By RT-PCR & Multiplexing (2013-2022) ($MN)
157 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Protein Microarrays (2013-2022) ($MN)
158 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Cellular capture and identification (2013-2022) ($MN)
159 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Next Generation Sequencing (2013-2022) ($MN)
160 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Benchtop Sequencers (2013-2022) ($MN)
161 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Other Technologies (2013-2022) ($MN)
162 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Function (2013-2022) ($MN)
163 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Prognosis Diagnostics (2013-2022) ($MN)
164 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Companion Diagnostics (2013-2022) ($MN)
165 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Cancer Screening (2013-2022) ($MN)
166 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Risk Analysis (2013-2022) ($MN)
167 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Therapeutic Monitoring (2013-2022) ($MN)
168 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Cancer Type (2013-2022) ($MN)
169 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Sex-related tumors (2013-2022) ($MN)
170 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Cervical Cancer (2013-2022) ($MN)
171 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Breast Cancer (2013-2022) ($MN)
172 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Ovarian Cancer (2013-2022) ($MN)
173 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Prostate Cancer (2013-2022) ($MN)
174 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Blood-born cancers (2013-2022) ($MN)
175 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Myeloma (2013-2022) ($MN)
176 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Leukemia (2013-2022) ($MN)
177 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Lymphoma (2013-2022) ($MN)
178 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Lung Cancer (2013-2022) ($MN)
179 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Solid tumors (2013-2022) ($MN)
180 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
181 Rest of the World Next Generation Cancer Diagnostics Market Outlook, By Other Cancers (2013-2022) ($MN)

 

1. What do I do if I have a query on this report?
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
2. Is the sample available for this report? Can I request the sample with my specific requirements?
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
3. Format of the report?
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
4. Services prior to purchase and after purchase?
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
5. License Type and Delivery?
We have 3 different licensing options available in electronic format.
  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment
6. Purchase procedure and Invoicing?
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards
7. Post sale support?
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

Select License Type

Single User License (PDF)

 

2 - 5 User License (PDF)

 

Site License (PDF)

 

Corporate License (PDF)

 

Have a Question?


Know our Methodology

WHY CHOOSE US ?

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Adding more values to your product of interest.

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials